NCCN Aids Oncologists in the Diagnosis and Treatment of Rare Histiocytic Neoplasms
January 12th 2022In an interview with Targeted Oncology, Ronald S. Go, MD, discussed the new guidelines for the diagnosis and treatment of histiocytic neoplasms, challenges with managing the disease, and toxicity management.
Read More
BLA for Beti-Cel in B-thalassemia Accepted for Priority Review by FDA
November 23rd 2021The newly accepted FDA approval application for betibeglogene autotemcel is supported by 5 studies of the agent across all ages of patients. Eighty-nine percent of evaluable patients achieved transfusion independence.
Read More
The Development of a Platform Designed to Activate NK Cells
November 11th 2021Jeffrey Miller, MD, discusses the background of the Tri-Specific Killer Engager TRICK platform for the activation of natural killer cells for the treatment of refractory tumors, including those that are hematology-based.
Watch